Cilostazol: a replacement for pentoxifylline?
Shukla V
Record ID 31999009741
English, French
Authors' objectives:
To summarise the available evidence on the use of cilostazol for the treatment of intermittent claudication (IC)
Authors' recommendations:
Based on the limited available evidence, cilostazol does not appear to have any advantage over pentoxifylline in terms of safety and efficacy. Keeping safety, efficacy and presumptive cost factors into consideration, there is a minimal chance that cilostazol will replace pentoxifylline at the present time.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
1999
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Costs and Cost Analysis
- Pentoxifylline
- Intermittent Claudication
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.